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Abstract
Background: G-protein-coupled receptor (GPCR) heteromeric complexes have distinct properties from homomeric GPCRs,
giving rise to new receptor functionalities. Adenosine receptors (A1R or A2AR) can form A1R-A2AR heteromers (A1-A2AHet),
and their activation leads to canonical G-protein-dependent (adenylate cyclase mediated) and -independent (β-arrestin
mediated) signaling. Adenosine has different affinities for A1R and A2AR, allowing the heteromeric receptor to detect its
concentration by integrating the downstream Gi- and Gs-dependent signals. cAMP accumulation and β-arrestin recruitment
assays have shown that, within the complex, activation of A2AR impedes signaling via A1R.
Results: We examined the mechanism by which A1-A2AHet integrates Gi- and Gs-dependent signals. A1R blockade by A2AR
in the A1-A2AHet is not observed in the absence of A2AR activation by agonists, in the absence of the C-terminal domain of
A2AR, or in the presence of synthetic peptides that disrupt the heteromer interface of A1-A2AHet, indicating that signaling
mediated by A1R and A2AR is controlled by both Gi and Gs proteins.
Conclusions: We identified a new mechanism of signal transduction that implies a cross-communication between Gi
and Gs proteins guided by the C-terminal tail of the A2AR. This mechanism provides the molecular basis for the
operation of the A1-A2AHet as an adenosine concentration-sensing device that modulates the signals originating at
both A1R and A2AR.
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Background
Adenosine is a purine nucleoside whose relevance in
the central nervous system is mainly due to its role
in regulating neurotransmitter release [1]. The effects
of adenosine are mediated by specific G-protein-
coupled receptors (GPCRs) that are coupled to either
Gs or Gi heterotrimeric Gαβγ proteins. The endogen-
ous adenosine acts on four receptor subtypes – A1R,
A2AR, A2BR, and A3R. Convergent and compelling
evidence shows that GPCRs may form complexes
constituted by a number of equal (homo) or different
(hetero) receptor protomers [2]. As agreed in the
field, a GPCR heteromer displays characteristics that
are different from those of the constituting proto-
mers, thus giving rise to novel functional entities [3].
Adenosine receptors have been used as a paradigm in
the study of receptor homo- and heteromerization.
For instance, A1R, which is Gi coupled, and A2AR,
which is Gs coupled, form a functional heteromer [4].
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The A1R-A2AR heteromer (A1-A2AHet) is found
presynaptically in, inter alia, cortical glutamatergic
terminals innervating the striatum and functions as a
switch that differentially senses high and low concen-
trations of adenosine in the inter-synaptic space. Since
adenosine has higher affinity for A1R than for A2AR, low
concentrations predominantly activate A1R, engaging a
Gi-mediated signaling, whereas higher adenosine concen-
trations also activate A2AR, engaging a Gs-mediated
signaling [4]. The physiological role of such a
concentration-sensing device is remarkable as it allows
adenosine to fine-tune modulate the release of neuro-
transmitters from presynaptic terminals. However, the
mechanism by which A1-A2AHet integrates both Gi- and
Gs-dependent signals is not yet understood. We have
recently shown, using a combination of single-particle
tracking experiments, bioluminescence resonance energy
transfer (BRET) assays, and computer modeling, that the
(minimal) functional A1-A2AHet/G protein unit is com-
posed by a compact rhombus-shaped heterotetramer
(with A1R and A2AR homodimers) bound to two different
interacting heterotrimeric G proteins (Gs and Gi) [5]. In
the present study, we aim to understand the molecu-
lar intricacies underlying the signaling mediated by
A1-A2AHet, in which (1) both receptors constituting
the heteromer are activated by the same endogenous
agonist and (2) is coupled to two different G proteins
with opposite effects, i.e., one mediating the inhibition
of the adenylate cyclase (Gi) and another mediating
the activation of the enzyme (Gs). Our data identifies
a new mechanism of signal transduction and provides
the molecular basis to understand the unique proper-
ties of this heteromer, in which the C-terminal tail of
the A2AR influences the Gi-mediated signaling of the
partner A1R receptor.
Results
Homodimerization of A1R and A2AR occurs through the
transmembrane (TM) 4/5 interface and heterodimerization
via the TM5/6 interface in the A1-A2AHet
Our recently published BRET-aided computational
model of the A1-A2AHet predicted the TM interfaces in-
volved in homo- (TM4/5) and heterodimerization
(TM5/6) [5]. To further confirm this arrangement, we
used synthetic peptides with the sequence of TM
domains of the A2AR (abbreviated TM1 to TM7) and
the A1R (abbreviated TM5 to TM7), fused to the cell-pe-
netrating HIV transactivator of transcription (TAT) pep-
tide [6], to alter inter-protomer interactions in the A1-
A2AHet. These peptides were first tested in bimolecular
fluorescence complementation (BiFC) assays in HEK-
293 T cells expressing receptors fused to two comple-
mentary halves of YFP (cYFP and nYFP) (see Methods).
We detected fluorescence in HEK-293 T cells transfected
with cDNAs for A2AR-nYFP, A2AR-cYFP, and non-fused
A1R (broken lines in Fig. 1a), indicating the formation of
the A2AR-A2AR homodimer. Notably, in the presence of
Fig. 1 Effect of interference peptides on the A1-A2AHet structure
determined by bimolecular fluorescence complementation (BiFC)
assays. a–e BiFC assays were performed in HEK-293 T cells
transfected with cDNAs (1 μg) for A2AR-nYFP, A2AR-cYFP, and
non-fused A1R (a) or A2AR-cYFP and A1R-nYFP (b–e). Cells were
pre-treated for 4 h with medium (control, broken lines) or with 4
μM of A2AR TM synthetic peptides (TM1 to TM7, green squares) or A1R
synthetic peptides (TM5 to TM7, orange squares). Subsequently, they
were left untreated (a, b) or activated for 10 min with the A1R agonist
CPA (c, 100 nM), the A2AR agonist CGS-21680 (d, 100 nM), or both (e).
Fluorescence was read at 530 nm. Mean ± SEM (13 experiments/
treatment). One-way ANOVA followed by a Dunnett’s multiple
comparison test showed a significant fluorescence decrease over
control values (*P < 0.05, **P < 0.01, ***P < 0.001). In each panel,
there is a schematic representation of the BiFC pairs and conditions. (f)
Schematic slice (left) and cartoon (right) representations of the A1-A2AHet
built using the predicted experimental interfaces
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interference peptides, we observed a fluorescence de-
crease only with TM4 and TM5 of A2AR (Fig. 1a), but
not with A1R TM peptides (Fig. 1a) or with peptides de-
rived from the orexin receptor (Additional file 1: Figure
S1A) used as negative controls. Further negative controls
show that A2AR peptides do not alter fluorescence in
HEK-293 T cells expressing A1R-nYFP and A1R-cYFP
(Additional file 1: Figure S1B). These results therefore
confirmed the TM4/5 interface for A2AR homodimeriza-
tion in the heteromer. Similarly, we detected fluores-
cence in cells expressing A1R-nYFP and A2AR-cYFP
(broken lines in Fig. 1b), indicating formation of the A1-
A2AHet. This fluorescence was only reduced in the pres-
ence of TM4, TM5, and TM6 peptides of A2AR (Fig. 1b).
The involvement of TM5/6 in the heteromer interface
was also confirmed by the fact that TM5 and TM6, but
not TM7, of A1R reduced fluorescence in cells express-
ing A1R-nYFP and A2AR-cYFP (Fig. 1b). These results
reinforce our previously proposed compact rhombus-
shaped arrangement of protomers in which heteromeri-
zation of A1-A2AHet occurs via the TM5/6 interface
(Fig. 1f ). The fluorescence decrease induced by TM4
A2AR peptide indicates that the correct homomerization is
a requisite for A1-A2AHet formation and/or that the TM4
peptide interferes with interactions of the TM4 of the ex-
ternal protomer of the A2AR homodimer with the internal
protomer of the A1R homodimer (Fig. 1f) [5]. Next, we
evaluated whether receptor activation, by the A1R-selective
agonist N6-cyclopentyladenosine (CPA), the A2AR-selective
agonist 4-[2-[[6-Amino-9-(N-ethyl-β-D-ribofuranuronami-
dosyl)-9H-purin-2-yl]amino]ethyl] benzenepropanoic acid
(CGS-21680), or both, modify the heteromer TM interface.
As clearly shown in Figs. 1c–e, none of the agonists, used
either individually (Figs. 1c, d) or in combination (Fig. 1e),
modified the effect of the TM peptides relative to the
ligand-free experiments. Therefore, no rearrangements of
the TM interface in the A1-A2AHet occurred upon recep-
tor activation.
Next, we investigated whether interference TM pep-
tides, which are able to alter the quaternary structure of
the A1-A2AHet as demonstrated by BiFC experiments,
are also able to disrupt the heteromer. To do this, prox-
imity ligation assays (PLA) were performed in HEK-293
T cells expressing A1R and A2AR. The PLA assay is a
powerful technique to detect protein-protein interac-
tions by assessing proximity between GPCR protomers
with high resolution (< 40 nm). A1-A2AHet was observed
as red punctate staining (Fig. 2), whereas pretreatment
of cells with TM4, TM5, TM6, and TM7 of A2AR did
not decrease PLA staining (Fig. 2), indicating that
interference peptides can alter the quaternary
structure of the heteromer but cannot disrupt
heteromerization.
The complex formed by Gs, Gi, and the A1-A2AHet as a
signal transduction unit
In order to test the ability of Gs and Gi proteins to interact
with the A1-A2AHet, we used BRET assays [7]. Cells were
transfected with cDNAs of A1R-nYFP and A2AR-cYFP,
which only upon complementation can act as a BRET
acceptor (YFP), and Renilla luciferase (Rluc) as a BRET
donor fused to either Gi (Gi-Rluc) or Gs (Gs-Rluc). We
observed significant energy transfer (Additional file 1:
Figure S1C), indicating that Gi and Gs are bound to their
respective receptors in the A1-A2AHet.
Next, we tested whether the A1-A2AHet can signal
through Gs- and Gi-dependent pathways by measuring
cAMP levels in cells expressing both A1R and A2AR. The
A1R-selective agonist CPA (100 nM, a concentration pro-
ducing maximal effect), which was unable to modify
cAMP levels in the absence of forskolin (Additional file 1:
Figure S2A), decreased forskolin-induced cAMP due to its
Gi coupling, and the A2AR-selective agonist CGS21680
(100 nM, a concentration producing maximal effect) in-
creased cAMP due to a Gs coupling (Fig. 3a, control), in-
dicating that both receptors signal via their cognate G
protein. We performed the same experiments in cells
treated with pertussis (PTX) or cholera (CTX) toxins,
which impair Gi- and Gs-mediated signaling, respectively,
and in cells transfected with minigenes that encode for
peptides blocking the interaction of the receptor with the
α subunits of Gi or Gs [8]. As expected, we observed
blockade of CPA-induced cAMP decrease by either PTX
(Fig. 3a) or the Gi-specific minigene (Fig. 3b), and block-
ade of CGS21680-induced cAMP increase by CTX
Fig. 2 Effect of interference peptides on the A1-A2AHet structure determined by proximity ligation assay (PLA) confocal microscopy images (superimposed
sections) in which A1-A2AHets appear as red spots. HEK-293 T cells expressing A1R and A2AR were treated for 4 h with medium (control) or 4 μM of
indicated TM peptides of A2AR; cell nuclei were stained with DAPI (blue); scale bars: 10 μm
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(Fig. 3a) or the Gs-specific minigene (Fig. 3b). Strikingly,
PTX or Gi-specific minigene (blocking Gi-receptor
interaction) also blocked the CGS21680-induced
cAMP increase (Fig. 3a, b). Moreover, CTX or the
Gs-specific minigene (blocking Gs-receptor inter-
action) also blocked the CPA-induced cAMP decrease
(Fig. 3a, b). Control experiments using these agonists
in cells expressing only A1R or A2AR did not show
any crossover effect with either toxins or minigenes
(Additional file 1: Figures S2B, C, E, F). These results
demonstrate that both A1R- and A2AR-mediated sig-
naling in the A1-A2AHet are dependent on the func-
tional integrity of both Gi and Gs proteins. According
to this, we observed by BRET experiments that the
A2AR agonist-induced interaction between A1-A2AHet
and Gs protein diminished in cells pre-treated with PTX
(Additional file 1: Figure S1D). We hypothesize that this
cross-communication could depend on the ability of α
subunits of Gi and Gs coupled to the A1-A2AHet to estab-
lish mutual interactions (see below).
To further test for a cross-communication between G
proteins in the Gs-Gi-heterotetramer signaling unit, we
resolved the real-time signaling signature by using a
label-free method, based on optical detection of dynamic
changes in cellular density following receptor activation
[9]. The magnitude of the signaling by CPA or by CGS
21680 significantly decreased when cells co-expressing
both receptors were pre-treated with either PTX or
CTX (Fig. 3d). This phenomenon was not observed in
cells expressing only A1R (Additional file 1: Figure S2G)
or A2AR (Additional file 1: Figure S2H). Again, these re-
sults indicate the simultaneous coupling of interacting
Gs and Gi proteins within the A1-A2AHet.
Simultaneous activation of both A1R and A2AR with
CPA and CGS21680 increased cAMP to similar levels to
those obtained with CGS21680 alone and the signal of
Fig. 3 Receptor signaling through the A1-A2AHet. Increases in cAMP percentage accumulation with respect to Fk-stimulated (a, b) or unstimulated (c) cells.
A1-A2AHet-expressed cells pre-treated with medium, PTX (10 ng/mL overnight) or CTX (100 ng/mL for 1 h) before adding medium, forskolin (Fk, 0.5 μM),
CPA (100 nM) plus/minus forskolin, CGS-21680 (100 nM) plus/minus forskolin, or CPA + CGS-21680. b Same assays in the absence or presence of 0.5 μg of
cDNA corresponding to Gi- or Gs-α-subunit-related minigenes. Mean ± SEM (7 experiments/group). One-way ANOVA followed by Bonferroni’s post-hoc test
in panels a, b showed a significant effect over basal in samples treated with CGS-21680 or over forskolin in samples treated with CPA; in panel c, a
significant effect is seen over basal (*P < 0.05, ***P < 0.001). d The dynamic mass redistribution analysis was plotted as pm shifts versus
time (Representative experiment, performed in triplicate). e, f Distances between the Cα atoms of Arg90 (αiAH domain) and Glu238 (Ras domain) of Gi
(in yellow), Asn112 (αsAH) and Asn261 (Ras) of Gs (green), Arg90 (αiAH) and Asn112 (αsAH) (dark red), and between the center of masses of the binding
sites of the Gi-unbound A1R and Gs-unbound A2AR protomers (black) obtained from two independent molecular dynamics (MD) simulations
of A1-A2AHet in complex with Gi and Gs in which αiAH was modelled in the closed conformation (Additional file 1: Figure S6C) and αsAH was
modelled in closed (e) or open (f) conformation. The computed distances are depicted as double arrows in the adjacent schematic representations.
Representative snapshots of the models are shown. Code: Gi-bound A1R/red, Gi-unbound A1R/orange, Gs-bound A2AR/light green, Gs-unbound A2AR/dark
green, α, β, and γ of Gi/Gs in dark gray/light gray/purple, respectively, TM4/light blue, TM5/gray, α-helical αiAH/green, and αsAH/yellow. g MD simulations
could not be performed for open conformations of αsAH and αiAH due to steric clash
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co-activated receptors was inhibited by both PTX and
CTX (Fig. 3c). Therefore, A1R agonist was able to de-
crease forskolin-induced cAMP (Fig. 3a, b) and yet was
unable to decrease A2AR-mediated increases of cAMP
(Fig. 3c). Consequently, when both receptors are co-
activated in the heterotetramer, only the A2AR-mediated,
but not the A1R-mediated signaling occurs. This finding
was confirmed in label-free experiments, showing that
receptor co-activation with CPA and CGS 21680 did not
increase the time-response curve with respect to the ac-
tivation with CGS 21680 alone (Fig. 3d green and yellow
lines, respectively).
It has been shown that the mechanism for receptor-
catalyzed nucleotide exchange in G proteins involves a
large-scale opening of the α-helical domain (αAH) of the
α-subunit, from the Ras domain, allowing GDP to freely
dissociate [10–13]. Notably, our proposed model of the
A1-A2AHet positions the αiAH and αsAH domains facing
each other (Fig. 3e). The fact that both Gs- and Gi-spe-
cific toxins and Gs- and Gi-specific minigenes affect both
Gs- and Gi-mediated coupling in the A1-A2AHet sug-
gests that the proposed large-scale conformational
changes of αAH domains is mutually dependent. We
used molecular dynamics (MD) simulations of the A1-
A2AHet in complex with Gs and Gi to evaluate intermo-
lecular distances between the αsAH and αiAH domains
when αiAH is in the closed conformation and αsAH is
either in the open (Fig. 3e) or in the closed conformation
(Fig. 3ef ). In a previous report, double electron–electron
resonance (DEER) distance distributions between spin
labels attached to Arg90 (αiAH domain) and Glu238
(Ras domain) of Gi (the distance between Cα atoms is
termed d[Arg90αi-Glu238αi] in the manuscript) or
Asn112 (αsAH) and Asn261 (Ras) of Gs (d[Asn112αs-
Asn261αs]) permitted to faithfully monitor the equilib-
rium within the open (distance of ~40 Å) and closed
(~20 Å) conformation of the αAH domain [13]. Here,
we measured the intermolecular distance between the
αsAH and αiAH domains using Cα atoms of Arg90 of αi
and Asn112 of αs (d[Arg90αi-Asn112αs]). This d[Arg90αi-
Asn112αs] intermolecular distance between αiAH in the
closed conformation (d[Arg90αi-Glu238αi]: 11 Å, yellow
line in Fig. 3e) and αsAH in the closed conformation
(d[Asn112αs-Asn261αs]: 14 Å, green line in Fig. 3e) has an
average value of 108 Å for inactive A1-A2AHet (Fig. 3e,
dark red line). Activation of A2AR would trigger the open-
ing of αsAH (d[Asn112αs-Asn261αs]: 52 Å; Fig. 3f, green
line), necessary for GDP/GTP exchange, decreasing the
d[Arg90αi-Asn112αs] distance between αiAH and αsAH to
60 Å (Fig. 3f, dark red line). Although the results are based
on a single trajectory, it is unlikely that additional repli-
cates would change, in a significant manner, the distances
reported from the simulations. Moreover, the differences
between the distances are so substantial that results from
more simulations would not have a significant impact. We
hypothesize that a similar change occurs with activation of
A1R. This indicates that both receptors can signal via their
cognate G protein by opening their αAH domain.
However, in the compact rhombus-shaped A1-A2AHet
model, simultaneous opening of both αAH domains
(co-activation with CPA and CGS 21680) would not be
possible due to a steric clash in such open conformations
(Fig. 3g). Due to this steric clash, MD simulations of this
open αiAH-open αsAH conformation in the absence of
interference peptides (see below) cannot be performed.
Altering the heteromer interface of A1-A2AHet enables
simultaneous Gi and Gs signaling
Next, we investigated whether the correct formation of
the A1-A2AHet is a necessary condition for the crosstalk
between the Gs- and Gi-signaling units using the inter-
ference peptides (TM4, TM5 and TM6 of A2AR, which
alter receptor heterodimerization, and TM7 as a negative
control). Remarkably, pretreatment of cells expressing
A1-A2AHet with the interference peptides did not
change receptor signaling when only one receptor is ac-
tivated (Fig. 4a). Interestingly, in the presence of TM4,
TM5 and TM6 peptides, simultaneous activation of both
A1R and A2AR with CPA and CGS21680, respectively,
allows CPA to decrease CGS21680-stimulated cAMP
(Fig. 4a), in contrast to experiments in the absence of ei-
ther interference peptides (Fig. 4a, control) or TM7 used
as a negative control (Fig. 4a). Moreover, this decrease in
cAMP accumulation in the CPA/CGS co-stimulated
condition is mediated by activation of the A1R/Gi path-
way as, in the presence of TM peptides, a selective A1R
antagonist or the treatment with PTX blocks the CPA-
induced effect (Additional file 1: Figure S2D). Thus,
modification of the quaternary structure of the A1-
A2AHet with peptides that penetrate within the hetero-
mer interface abolishes inhibition of A1R by A2AR in the
Gs-Gi-heterotetramer signaling unit. These experimental
results suggest that synthetic peptides inserted between
A1R and A2AR protomers, which are not able to disrupt
the heteromer as seen by PLA (Fig. 2), increase the dis-
tance between Gi and Gs. This would allow the simul-
taneous opening of αiAH and αsAH domains for GDP
dissociation. In order to verify this hypothesis, we mod-
eled the A1-A2AHet with the TAT-fused peptide TM6 al-
tering the heteromer interface between A1R and A2AR,
in complex with Gs (open αsAH, d[Asn112αs-Asn261αs]:
56 Å; Fig. 4b, green line) and Gi (open αiAH, d[Arg90αi-
Glu238αi]: 52 Å; Fig. 4b, yellow line). Due to the inser-
tion of TM6, the distance between the binding site of
A1R and A2AR increases by 17 Å, from 14 Å in the
absence of TM6 (Fig. 3e, f, black line) to 31 Å in the
presence of TM6 (Fig. 4b, black line). This increase in
the distance between heteromers also moves the
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intracellular αiAH and αsAH domains apart, thus
permitting their simultaneous opening (d[Arg90αi-
Asn112αs]: 10 Å; Fig. 4b, dark red line) for GDP/GTP
exchange.
A1-A2AHet as an adenosine concentration-sensing device
In order to illustrate the molecular device allowing ad-
enosine to signal by one or the other receptor [4], we
measured cAMP levels at increasing concentrations of
adenosine in cells expressing the A1-A2AHet (Fig. 5a).
Due to the higher affinity for the hormone, adenosine at
a low concentration (30 nM) binds predominantly to
A1R and engages a Gi-mediated signaling, which
significantly decreases forskolin-induced cAMP accumu-
lation. At higher concentrations, adenosine progressively
binds to A2AR, which engages a Gs-mediated signaling.
At high adenosine concentrations, full occupancy of
both A1R and A2AR leads to marked increases in cAMP
levels compatible with Gs activation and blockade of Gi,
as depicted in the schemes of Fig. 5a. In these condi-
tions, full active A2AR can increase cAMP over the
forskolin-induced levels whilst the progressive blockade
of A1R by A2AR cannot reduce cAMP accumulations.
To demonstrate such blockade of A1R actions by A2AR,
we performed the experiments in the presence of a pep-
tide (A2AR TM6) that inserts into the heteromer interface
(Fig. 5b). In the presence of the peptide, the device lost its
concentration-sensing properties. In fact, high adenosine
concentrations, in which both receptors are fully occupied
and functional, led to a null response, i.e., the A2AR-medi-
ated increase in forskolin-stimulated cAMP is counter-
acted by a similar Gi-mediated decrease of cAMP. Upon
heteromer structure alteration by TM6, the A2AR
becomes unable to block A1R-mediated signaling.
Recruitment of β-arrestin-2 by the A1-A2AHet
We used BRET assays to detect the interaction between
a protomer and β-arrestin-2. Thus, cells were transfected
with cDNAs of β-arrestin-2 fused to Rluc (Arr-Rluc) as
the BRET donor and A1R or A2AR fused to YFP
(A1R-YFP, A2AR-YFP) as the BRET acceptor. Control
experiments in cells expressing only A1R-YFP or
A2AR-YFP and Arr-Rluc show the ability of both recep-
tors to recruit β-arrestin-2 (Additional file 1: Figure
S3A) and the selectivity of each agonist (Additional file
1: Figure S3B). Similar experiments in cells additionally
expressing non-fused A2AR (Arr-Rluc/A1R-YFP + A2AR)
or non-fused A1R (Arr-Rluc/A2AR-YFP + A1R) were per-
formed (Additional file 1: Figure S3B). Interestingly, in
cells expressing Arr-Rluc, A2AR-YFP and non-fused A1R
(control in Fig. 6a and Additional file 1: Figure S3B) or
Arr-Rluc, A1R-YFP and non-fused A2AR (control in
Fig. 6b and Additional file 1: Figure S3B), a similar de-
gree of BRET was induced by CGS-21680 (white bars)
or by CGS-21680 plus CPA (striped bars). This suggests
that agonist binding to A2AR inhibits the CPA ability to
stimulate β-arrestin-2 recruitment to A1R. In order to
rationalize these results, we have used the recent crystal
structure of rhodopsin bound to visual arrestin-1 [14] to
model the A1-A2AHet in complex with β-arrestin-2. The
finger loop of arrestin, which adopts a short α-helix, is
inserted into the intracellular cavity of the external pro-
tomer, whereas the C-domain of arrestin points towards
the internal protomer of the homodimer. Figure 6c
shows key intermolecular distances between the center
of mass of the N- and C-domains of two arrestin mole-
cules bound to A1R and A2AR obtained from MD
Fig. 4 Effect of interference peptides on receptor signaling. a cAMP
production was determined in HEK-293 T cells transfected with 0.4
μg of A1R and A2AR cDNAs. Cells were treated for 4 h with medium
(control) or with 4 μM A2AR TM synthetic peptides (TM1 to TM7, see
Methods). Cells were unstimulated (basal, dotted line) or stimulated
with forskolin (Fk, 0.5 μM, gray bars), with forskolin and the A1R
agonist CPA (100 nM, black bars), the A2AR agonist CGS-21680 (100
nM, white bars), or with CPA and CGS-21680 (striped bars). Increases
in cAMP percentage accumulation in relation to unstimulated cells.
Mean ± SEM (7 experiments/condition). One-way ANOVA followed
by Bonferroni’s post-hoc test showed a significant effect over basal
in samples treated with CGS-21680 or CGS-21680 plus CPA, or over
forskolin in samples treated with CPA (*P < 0.05, **P < 0.01, ***P < 0.001).
One-way ANOVA followed by Bonferroni’s post-hoc test showed a
significant effect over control in the absence of peptide (&P < 0.05,
&&P < 0.01). b Intermolecular distances (depicted as double arrows in
the adjacent schematic representation) were obtained from MD
simulations of A1-A2AHet in complex with Gi and Gs (αiAH and
αsAH were modeled in the open conformation, see Additional
file 1: Figure S2B) in the presence of the TAT-fused TM6 peptide,
which alters the heteromer interface between A1R and A2AR. A
representative snapshot of the molecular model is shown, viewed from
the intracellular site. The TAT-TM6 peptide is shown in purple, whereas
the color code of the depicted proteins is as in Fig. 3
Navarro et al. BMC Biology  (2018) 16:24 Page 6 of 15
simulations. These data suggest that the A1-A2AHet qua-
ternary structure permits the binding of two arrestin
molecules to the external protomers of both A1R and
A2AR, similarly to the simultaneous binding of Gi and
Gs to the heterotetramer. Moreover, similar simulations
of A1-A2AHet in complex with Gi and β-arrestin-2 (Fig.
6d) show no steric clashes between Gi (bound to A1R)
and arrestin (bound to A2AR). These results suggest that
sustained activation of Gs (Gβγ moving away from Gαs to
facilitate the interaction of Gαs with the catalytic domain
of adenylate cyclase) by agonist binding to A2AR enables
β-arrestin-2 recruitment to A2AR. As stated above,
within the A1-A2AHet, CPA cannot activate Gi in the
presence of the A2AR agonist CGS-21680 (Fig. 3) and,
consequently, CPA does not trigger additional
β-arrestin-2 recruitment to A1R (control in Figs. 6a, b
and Additional file 1: Figure S3B).
Using the TAT-fused synthetic peptides we investi-
gated whether the quaternary structure of the A1-
A2AHet determines its putative selective A2AR-
dependent β-arrestin-2 recruitment. As a negative
control, we first corroborated that TM4, TM5, and
TM6 peptides of A2AR do not interfere with A1R-me-
diated signaling (Additional file 1: Figure S3C). Pre-
treatment of cells expressing Arr-Rluc, A2AR-YFP and
non-fused A1R (Fig. 6a), or Arr-Rluc, A1R-YFP and
non-fused A2AR (Fig. 6b) with TM4, TM5, and TM6
peptides, but not in the absence of peptides (control)
or with the TM7 peptide (negative control), allowed
the detection of positive BRET (recruitment of
β-arrestin-2) not only when cells were treated with
the A2AR-selective agonist CGS-21680 (white bars),
but also when treated with the A1R-selective agonist
CPA (black bars) (Figs. 6a, b). Importantly, when cells
expressing Arr-Rluc, A2AR-YFP, and non-fused A1R
were co-activated by CPA and CGS-21680 (striped
bars), BRET measurement in the presence of TM4,
TM5, or TM6 peptides, but neither in the absence of
peptides nor in the presence of TM7 peptide, signifi-
cantly increased relative to the values obtained by the
action of a single agonist (Fig. 6a). The trend is similar in
cells expressing Arr-Rluc, A1R-YFP, and non-fused A2AR,
but not statistically significant (Fig. 6b). These results indi-
cate that alteration of the A1R-A2AR heteromer interface
within the A1-A2AHet allows simultaneous recruitment of
β-arrestin-2 to A1R and A2AR when both receptors are acti-
vated. Interference peptides abolish cross-communication
of G proteins, permitting CPA to activate Gi (Gβγ moving
away from Gαi) and recruitment of β-arrestin-2 to A1R, as
well as Gs activation by CGS-21680 (Gβγ moving away from
Gαs) and simultaneous recruitment of β-arrestin-2 to A2AR.
The C-terminal domain of A2AR is responsible for the
dominant A2AR-mediated signaling
Despite the apparent structural symmetry of the GPCR/
G protein macromolecular complex, a major difference
Fig. 5 A1-A2AHet as an adenosine concentration-sensing device. A1-A2AHet-expressed cells were treated for 4 h with medium (a) or with 4 μM of
the synthetic A2AR TM6 peptide (b). Cells were stimulated with forskolin (Fk, 0.5 μM, red broken line) and adenosine at increasing concentrations
(30–3000 nM, black bars). cAMP levels were expressed as percentage over unstimulated cells (basal, 100%). Mean ± SEM of (7 experiments/condition).
One-way ANOVA followed by a Dunnett’s multiple comparison tests showed statistical differences relative to cells stimulated only with
forskolin (**P < 0.01, ***P < 0.001). Bottom panels show schemes that may provide an explanation of the results obtained at each adenosine
concentration. (1) The higher affinity of adenosine for A1R than for A2AR is illustrated by the size of the black lines at the binding site (adenosine is
shown as gray rectangles). (2) Adenosine-induced A1R and A2AR activation are depicted as arrows in pink and green, respectively, starting
at the binding site of each receptor. (3) A1R-induced Gi activation and A2AR-induced Gs activation, with the corresponding decrease/increase of cAMP,
are depicted as arrows in pink and green, respectively. The inhibitory effect of Gs on Gi-mediated signaling is shown as a red arrow. Width of arrows
illustrates the magnitude of receptor or G protein activation or cross-talk. High adenosine concentrations increase the A2AR binding (gray rectangle),
the adenosine-induced A2AR activation, the A2AR-induced GS activation (green arrows) and the cross-talk among G proteins (red arrow), while decreasing
the A1R-induced Gi activation (pink arrow) due to the cross-talk. In the presence of TM6 (in purple) the cross-talk among G proteins is
lost, enabling simultaneous A1R-induced Gi activation (pink arrow) and A2AR-induced GS activation (green arrow)
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is the length of the intracellular C-terminal domain of
adenosine receptors (16 amino acids in A1R versus 102
in A2AR). The short C-terminal tail of the A1R does not
have any known specific function, while the C-terminus
of A2AR, albeit dispensable for ligand binding [15],
dimerization [16], and agonist induced cAMP signaling
[17], influences constitutive signaling [18]. Due to the
shorter C-terminus of A1R and the proposed orientation
of the C-tail of A2AR toward αsAH (see Additional file 1:
Figure S4a for details), as well as the proposed role of
the C-terminal tail in downstream signaling cascade acti-
vation [19], we speculated that the C-terminus of A2AR
could modulate the prevailing Gs-mediated signaling
upon A1R and A2AR co-activation. To test this hypoth-
esis, we engineered two A2AR mutants, one lacking most
of the C-terminal end (A2A
ΔCTR) and another lacking the
last 40 amino acids (A2A
Δ40R). First, we tested whether
these truncated versions of A2AR could form heteromers
with A1R. We observed similar BRET saturation curves
in HEK-293 T cells expressing a constant amount of
A1R-Rluc cDNA and increasing amounts of either A2AR-
YFP, A2A
Δ40R-YFP, or A2A
ΔCTR-YFP, indicating that A2A
Δ40R
and A2A
ΔCTR form heteromers with A1R (Fig. 7a; BRETmax
in mU: 91 ± 3 A2AR, 99 ± 3 A2A
Δ40R, and 90 ± 8 A2A
ΔCTR).
Heteromers were also detected by BiFC assays in HEK-
293 T cells transfected with cDNAs for A1R-nYFP and
A2A
ΔCTR-cYFP (Fig. 7b, dashed line). In these cells, fluor-
escence was reduced in the presence of TM4, TM5,
and TM6 peptides of A2AR (Fig. 7b). Thus,
heteromerization of A2A
ΔCTR with A1R occurs via the
TM5/6 interface, similarly to the interaction of A2AR
with A1R.
We measured cAMP production in cells expressing
A1R and wild-type or truncated A2AR receptors (Fig. 7c).
Fig. 6 Effect of interference peptides on recruitment of β-arrestin-2. a, b Receptor agonist-induced β-arrestin-2 recruitment was measured by
BRET. HEK-293 T cells were transfected with the cDNAs for β-arrestin-2-Rluc (Arr-Rluc, 0.5 μg cDNA) and either A2A-YFP (0.4 μg cDNA) and A1R
(0.4 μg cDNA) (a) or A1-YFP (0.4 μg cDNA) and A2AR (0.4 μg cDNA) (b). Cells were untreated (control) or treated for 4 h with 4 μM A2AR TAT-TM
synthetic peptides (TM4–7, see Methods) before addition of medium (basal, gray bars) or 100 nM of either the A1R agonist CPA (black bars), the
A2AR agonist CGS-21680 (CGS, white bars), or both (striped bars). Positive BRET was expressed as milli-BRET units (see Methods). Mean ± SEM
(7 experiments/condition). One-way ANOVA followed by Bonferroni’s post-hoc test showed a significant effect over basal in samples treated with
CGS-21680 or over forskolin in samples treated with CPA (*P < 0.05, **P < 0.01, ***P < 0.001). One-way ANOVA followed by Bonferroni’s post-hoc
test showed a significant effect of CPA + CGS-21680 over CGS-21680 treatments (&P < 0.05, &&P < 0.01). c Intermolecular distances between the
center of masses of the N- and C-domains of the A1R-bound arrestin and of the A2AR-bound arrestin obtained from molecular dynamics (MD)
simulations of A1-A2AHet in complex with two molecules of β-arrestin-2. d Intermolecular distances between the center of mass of the N- and
C-domains of the A2AR-bound arrestin and the Cα atom of Glu238 (RAS domain) of Gi obtained from MD simulations of A1-A2AHet in complex
with Gi bound to A1R and β-arrestin-2 bound to A2AR. These intermolecular distances are depicted as double arrows in the adjacent representative
snapshots of the molecular models. Arrestin is shown in gray, whereas the color code of the depicted proteins is as in Fig. 3
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Truncated A2AR were able to signal as wild-type recep-
tors. Interestingly, the dominant Gs-mediated signaling
when A1R and A2AR were co-activated decreased progres-
sively with the shortening of the A2AR C-tail (Fig. 7c,
striped bars). In fact, CPA inhibited CGS-21680-induced
cAMP accumulation when truncated receptors were
expressed, showing that, in these heteromers, A1R were
functional (Additional file 1: Figure S5). Figure 7e shows a
detailed view of the orientation of the C-tail (102 amino
acids, Gln311-Ser412) of both A2AR protomers in the A1-
A2AHet, which was modeled as suggested for the OXER
[20], together with the structure of β-arrestin-2 in complex
with V2 vasopressin receptor [21]. It is important to note
that the exact conformation of the A2AR C-tail cannot un-
ambiguously be determined, thus, we only predict its orien-
tation as explained in detail in Additional file 1: Figure S4.
The fact that the C-tail of the αs-unbound A2AR protomer
points toward the αsAH domain suggests that this C-tail is
influencing the conformational changes required to open
the αsAH, and thus controlling the balance between Gs and
Gi activation. Next, we measured β-arrestin-2 recruitment
by BRET assays in cells expressing A1R and wild-type or
truncated A2AR receptors. In cells expressing non-fused
A1R, Arr-Rluc and A2AR-YFP, A2A
Δ40R-YFP, or A2A
ΔCTR-YFP,
the A1R agonist CPA could increase BRET values only
when the heteromer is formed with A2AR-truncated recep-
tors. In these conditions, co-activation with CPA and CGS-
21860 induced a BRET increase higher than the one
obtained with CGS-21680 alone (Fig. 7d). These results
indicate that the selective A2AR-dependent β-arrestin-2 re-
cruitment in the A1-A2AHet decreases progressively with
the shortening of the A2AR C-tail (Fig. 7d).
Fig. 7 Influence of A2AR C-terminal domain over signaling properties of A1-A2AHets. a BRET in cells expressing constant A1-Rluc amount (0.4 μg
cDNA) and increasing (0.1–0.7 μg cDNA) amounts of A2A
Δ40R-YFP or A2A
ΔCTR-YFP. Mean of milli-BRET units ± SEM (n = 7). b BiFC assays (fluorescence
measured at 530 nm) were performed in cells expressing (1 μg cDNA) A1R-nYFP and A2AΔCTR-cYFP and pre-treated for 4 h with medium or 4 μM
A2AR-TM peptides (TM1–7). Mean ± SEM (13 experiments/treatment). One-way ANOVA followed by a Dunnett’s multiple comparison test showed
a significant fluorescence decrease over control values (***P < 0.001). c HEK-293 T cells expressing A1R (0.4 μg cDNA) and A2AR (0.3 μg cDNA),
A2A
Δ40R (0.3 μg cDNA), or A2AΔCTR (0.3 μg cDNA) were unstimulated (basal, dotted line) or stimulated with forskolin (Fk, 0.5 μM, gray bars), with
forskolin and CPA (100 nM, black bars), CGS-21680 (CGS, 100 nM, white bars), or with CPA + CGS-21680 (striped bars). cAMP percentage
accumulation over unstimulated cells. Mean ± SEM (7 experiments/group). One-way ANOVA followed by Bonferroni’s post-hoc test: significant effect
over basal in CGS-21680-stimulated samples or over forskolin-stimulated cells (**P < 0.01, ***P < 0.001) or CPA + CGS-21680 over CGS-21680-stimulated
cells (&&&P < 0.001). d HEK-293 T cells expressing β-arrestin-2-Rluc (Arr-Rluc, 0.5 μg cDNA), A1-YFP (0.4 μg) and A2AR (0.3 μg), A2AΔ40R (0.3 μg), or A2AΔCTR
(0.3 μg). Cells stimulated with agonists as indicated. Mean ± SEM (7 experiments/condition). One-way ANOVA followed by the Bonferroni’s post-hoc
test: significant differences over unstimulated cells (*P < 0.05, ***P < 0.001) or CPA-CGS-21680 over CGS-21680-stimulated cells (&P < 0.05, &&P < 0.01).
e Molecular model of the A2AR homodimer in complex with Gs. TMs involved in homodimerization: TM4/light blue and TM5/gray; color code of
proteins is as in Fig. 3. C-tail of Gsα-subunit-unbound A2AR protomer is near αsAH (shown in closed conformation)
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Discussion
As previously reviewed [2, 3, 22], the intercommunica-
tion between protomers of a GPCR heteromer can be
observed at the level of agonist binding, ligand-induced
cross-conformational changes between receptor proto-
mers, and the binding of GPCR-associated proteins,
including heterotrimeric G proteins and β-arrestins. The
intercommunication between protomers is a conse-
quence of a defined quaternary structure that is respon-
sible for the specific functional characteristics of the
heteromer. For GPCR heteromers, such as A1-A2AHet,
constituted by receptors sensing the same hormone
but producing opposite signaling effects, it is not ob-
vious how a defined quaternary structure achieves this
dual behavior. A1-A2AHet acts as a concentration-
sensing device that allows adenosine to signal by one
or the other coupled G protein (Gs or Gi) to fine-
tune modulate the release of neurotransmitters from
presynaptic terminals. In the present study, we solved
this question by discovering a new mechanism of
signal transduction, a cross-communication between
Gi and Gs in the A1-A2AHet guided by the A2AR C-
terminal domain.
We have shown that cross-communication between Gi
and Gs proteins involves the formation of a GPCR het-
erotetramer (i.e., one homodimer of A1R and one of
A2AR) that has a 2:2:1:1 (A2AR:A1R:Gs:Gi) stoichiometry.
From our data, it is deduced that the cross-talk between
Gi and Gs resides on the structural constraints surround-
ing the mechanism for GDP/GTP exchange, which in-
volves the opening of the αAH domain of the α-subunit
of any given G protein. We propose that cross-
communication in the Gs-Gi-heterotetramer signaling
unit is a property associated with a specific quaternary
structure, the compact rhombus-shaped A1-A2AHet (the
TM4/5 interface for homodimerization and the TM5/6
interface for heterodimerization), which positions the
αiAH and αsAH domains in close proximity, making
their conformational changes mutually dependent in a
way that simultaneous opening of both αAH domains
would not be possible due to a steric clash in such open
conformations. Alterations of this quaternary structure
of the A1-A2AHet by insertion of synthetic peptides be-
tween A1R and A2AR blocks this cross-communication
without disrupting the heteromer and permits simultan-
eous activation of Gi and Gs in the heteromer. Since the
cross-talk between Gi and Gs resides on the structural
constraints imposed by defined TM interfaces in the het-
eromer, it is important to note that other heterotetra-
mers, mainly those sensing different hormones and with
a different quaternary structure, might not display this
cross-communication among G proteins. Moreover, al-
though, from a structural point of view, the A1-A2AHet
is capable to recruit not only two G proteins but also
two β-arrestins, the cross-talk between Gi and Gs, in
which Gs activation inhibits the simultaneous activa-
tion of Gi, blocks A1R agonist-promoted arrestin re-
cruitment. Alteration of the A1-A2AHet by insertion
of synthetic peptides between A1R and A2AR facili-
tates simultaneous activation of Gi and Gs and the
corresponding binding of two β-arrestins to A1R and
A2AR. Our finding that Gi is dependent on Gs-medi-
ated signaling strengthens the conclusion that cross-
talk across G proteins is a potentially important
functional property of GPCR heteromers. Remark-
ably, when both receptors are co-activated in this
heterotetramer, only A2AR-mediated, but not A1R-
mediated signaling occurs. We show that the ability
of blunting A1R-mediated signaling when Gs is en-
gaged is dependent of the long C-terminus of the
A2AR. In the absence of A2AR activation by agonists,
or in the absence of the C-terminal domain of A2AR,
the A1R-mediated signaling via Gi is totally func-
tional. The most straightforward hypothesis is that
the opening of αsAH parallels a movement of the
C-tail to block the opening of αiAH.
Adenosinergic signaling in mammalians is important
for energy and temperature homeostasis and for neuror-
egulation. Multiplicity of adenosine actions is due to a
balance between the expression of specific receptors and
producing/degrading enzymes and to the biological di-
versity due to a membrane network established by the
interaction among purinergic receptors [23]. Ciruela et
al. [4] first identified the occurrence of heteromers
formed by A1R-Gi- and A2A-Gs-coupled adenosine
receptors that participate in the regulation of glutamate
release by neurons projecting from the cortex to the stri-
atum. The same A1-A2AHet can be found in astrocytes
modulating the transport of γ-amino butyric acid
(GABA) [24]. Differently from the modulation of neur-
onal glutamate release, the A1R-Gi-coupled receptor ac-
tivates and the A2AR-Gs-coupled receptor inhibits the
modulation of GABA transport. Under conditions of
high extracellular adenosine concentrations, such as
hypoxic conditions [25], the nucleoside will bind to both
the high (A1R) and the low (A2AR) affinity receptors in
the heteromer, and the predominant A2AR-mediated sig-
naling via Gs will result in counteraction of astrocytic
GABA transport. Our results show that the asymmetric
signaling is possible because the long C-terminus of
A2AR blunts Gi-mediated signaling. We have therefore
elucidated the mechanism by which the A1-A2AHet
functions as an adenosine concentration-sensing device
that can promote even opposite signaling responses de-
pending on the extracellular concentration of adenosine.
The molecular mechanism involves the C-terminal do-
main of the activated Gs-coupled A2AR, which hinders
the activation of A1R coupled to Gi.
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Conclusions
Using a convergent approach including biochemical, bio-
physical, cell biology, and molecular biology techniques,
together with in silico molecular models, we here pro-
vide the mode of action of a membrane receptor com-
plex that responds depending on the concentration of
adenosine, a hormone and a neuroregulatory molecule.
The concentration sensor is a heteromer composed of
four adenosine receptors (two A1 and two A2A) and two
G proteins (Gi and Gs). Despite Gi sits underneath the
A1 receptor dimer and Gs sits underneath the A2A re-
ceptor dimer, both G proteins do interact and are able
to convey allosteric regulation depending on how the
functional unit is activated. At low adenosine concentra-
tions Gi is engaged via A1 activation without affecting/
engaging Gs signaling. At higher concentrations Gs is
engaged via A2A activation, and this engagement blocks
Gi-mediated signaling. The reason why a rhombus-
shaped apparently symmetric structure results in asym-
metric signaling is due to the long C-terminal tail of the
A2A receptor. In fact, both deletion of the C-terminal
end or treatment with interfering peptides derived from
the sequence of TM segments of the receptors impair
allosteric cross-interaction between receptors and G
proteins within the macromolecule, and the device loses
its concentration sensing properties.
Methods
Cell culture and transient transfection
HEK-293 T cells were grown at 37 °C in in Dulbecco’s
modified Eagle’s medium (DMEM) (Gibco) supple-
mented with 2 mM L-glutamine, 100 U/mL penicillin/
streptomycin, and 5% (v/v) heat inactivated fetal bovine
serum (all supplements were from Invitrogen, Paisley,
Scotland, UK). Cells were transiently transfected with
cDNA corresponding to receptors, fusion proteins, A2AR
mutant constructs, or minigene vectors using polyethy-
lenimine (Sigma-Aldrich, Cerdanyola del Vallés, Spain)
as described elsewhere [7].
Expression vectors, A2AR mutants and minigenes
Sequences encoding amino acid residues 1–155 or
155–238 of YFP-Venus protein, were subcloned in
pcDNA3.1 to obtain the YFP Venus hemi-truncated pro-
teins (nYFP and cYFP). The human cDNAs for A2AR, mu-
tant A2AR, A1R, and Gi or Gs proteins cloned into
pcDNA3.1, were amplified without their stop codons
using sense and antisense primers harboring unique EcoRI
and BamHI sites to subclone receptors in pcDNA3.1RLuc
vector (pRLuc-N1 PerkinElmer, Wellesley, MA, USA) and
EcoRI and KpnI to subclone receptors in pEYFP-N1
(enhanced yellow variant of GFP; Clontech, Heidelberg,
Germany), pcDNA3.1-nVenus, or pcDNA3.1-cVenus
vectors. The amplified fragments were subcloned to be in-
frame with restriction sites of the corresponding vectors to
give the plasmids that express receptors fused to RLuc,
YFP, nYFP or cYFP on the C-terminal end (A1R-Rluc,
A2AR-Rluc, Gi-RLuc, Gs-RLuc, A1R-YFP, A2AR-YFP,
A2A
Δ40R-YFP, A2A
ΔCTR-YFP, A1R-nYFP, A2A-nYFP, and A2A-
cYFP). Expression of constructs was tested by confocal mi-
croscopy and the receptor-fusion protein functionality by
second messengers, ERK1/2 phosphorylation and cAMP
production as described previously [4, 26–28]. Mutants
with a deletion of aa 372 to aa 412 (A2A
Δ40R) or aa 321 to aa
412 (A2A
ΔCTR) on the C-terminal domain of A2AR were gen-
erated as previously described [29]. “Minigene” plasmid
vectors are constructs designed to express relatively short
polypeptide sequences following their transfection into
mammalian cells. Here, we used minigene constructs
encoding 11 amino acid residues from the C-terminus
sequence of α subunit of Gi1/2 or Gs. The peptide
coded by every minigene inhibits the coupling of the
G (Gi1/2 or Gs) protein to the receptor and, conse-
quently, it inhibits the G-protein-mediated cellular
response, as previously described [8]. The cDNA encoding
the last 11 amino acids of human Gα subunit correspond-
ing to Gi1/2 (IKNNLKDCGLF) or Gs (QRMHLRQYELL),
inserted in a pcDNA 3.1 plasmid vector, was generously
provided by Dr. Heidi Hamm.
TAT-TM peptides
Peptides with the sequence of the TM of A1R and A2AR
fused to the HIV TAT peptide (YGRKKRRQRRR) were
used as oligomer-disrupting molecules (synthesized by Gen-
emad Synthesis Inc. San Antonio, TX, USA). The cell-
penetrating TAT peptide allows intracellular delivery of
fused peptides [6]. The TAT-fused TM peptide can then be
inserted effectively into the plasma membrane because of
the penetration capacity of the TAT peptide and the hydro-
phobic property of the TM moiety [30]. To obtain the right
orientation of the inserted peptide, the HIV-TAT peptide
was fused to the C-terminus or to the N-terminus as
indicated:
MEYMVYFNFFVWVLPPLLLMVLIYLYGRKKRRQRRR
for TM5 of A1R,
RRRQRRKKRGYLALILFLFALSWLPLHILNCITLF for
TM6 of A1R,
ILTYIAIFLTHGNSAMNPIVYAFRIYGRKKRRQRRR
for TM7 of A1R,
VYITVELAIAVLAILGNVLVCWAVWYGRKKRRQRRR
for TM1 of A2AR,
YGRKKRRQRRRYFVVSLAAADIAVGVLAIPFAITI for
TM2 of A2AR,
LFIACFVLVLTQSSIFSLLAIAIYGRKKRRQRRR for
TM3 of A2AR,
YGRKKRRQRRRAKGIIAICWVLSFAIGLTPMLGW for
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TM4 of A2AR,
MNYMVYFNFFACVLVPLLLMLGVYLYGRKKRRQRR
R for TM5 of A2AR,
YGRKKRRQRRRLAIIVGLFALCWLPLHIINCFTFF for
TM6 of A2AR,
LWLMYLAIVLSHTNSVVNPFIYAYYGRKKRRQRRR
for TM7 of A2AR.
YGRKKRRQRRRILGIWAVSLAIMVPQAAVME for
TM4 of OX1R,
SSFFIVTYLAPLGLMAMAYFQIFYGRKKRRQRRR for
TM5 of OX1R,
YASFTFSHWLVYANSAANPIIYNFYGRKKRRQRRR
for TM7 of OX1R
Bimolecular fluorescence complementation assay (BiFC)
HEK-293 T cells were transiently transfected with equal
amounts of the cDNA for fusion proteins of the hemi-
truncated Venus (1 μg of each cDNA). At 48 h after
transfection, cells were treated for 4 h at 37° with
medium or TAT peptides (4 μM) before plating 20 μg of
protein in 96-well black microplates (Porvair, King’s
lynn, UK). To quantify reconstituted YFP Venus expres-
sion, fluorescence at 530 nm was read in a Fluoro Star
Optima Fluorimeter (BMG Labtechnologies, Offenburg,
Germany) equipped with a high-energy xenon flash
lamp, using a 10 nm bandwidth excitation filter at 400
nm reading. Protein fluorescence expression was deter-
mined as fluorescence of the sample minus the fluores-
cence of cells not expressing the fusion proteins (basal).
Cells expressing receptor-cVenus and nVenus or
receptor-nVenus and cVenus showed similar fluorescence
levels than untransfected cells.
Bioluminescence resonance energy transfer (BRET)
HEK-293 T cells were transiently transfected with a
constant amount of cDNA for Rluc fusion proteins and
increasing amounts of cDNA for YFP fusion proteins. At
48 h after transfection, 20 μg of cell suspension were
plated in 96-well black microplates for fluorescence de-
tection or in 96-well white microplates for BRET read-
ings and Rluc quantification. YFP fluorescence at 530
nm was quantified in a Fluoro Star Optima Fluorimeter
as described above. BRET signal was collected 1 min
after addition of 5 μM coelenterazine H (Molecular
Probes, Eugene, OR, USA) using a Mithras LB 940. The
integration of the signals detected in the short-
wavelength filter at 485 nm and the long-wavelength fil-
ter at 530 nm was recorded. To quantify protein-RLuc
expression, luminescence readings were also performed
after 10 minutes of adding 5 μM coelenterazine H. The
net BRET is defined as (long-wavelength emission/short-
wavelength emission)–Cf, where Cf corresponds to long-
wavelength emission/short-wavelength emission for the
donor construct expressed alone in the same experi-
ment. BRET is expressed as milli-BRET units (net BRET
× 1000). To calculate maximum BRET (BRETmax) from
saturation curves, data were fitted to a nonlinear regres-
sion equation, assuming a single-phase saturation curve
with GraphPad Prism software (San Diego, CA, USA).
Proximity ligation assay (PLA)
HEK293T cells were grown on glass coverslips and fixed
in 4% paraformaldehyde for 15 min, washed with
phosphate-buffered saline containing 20 mM glycine,
permeabilized with the same buffer containing 0.05%
Triton X-100, and successively washed with tris-buffered
saline. Heteromers were detected using the Duolink II in
situ PLA detection Kit (OLink; Bioscience, Uppsala,
Sweden) following supplier’s instructions. A mixture of
the primary antibodies (mouse anti-A2AR antibody (1:100;
05-717, Millipore, Darmstadt, Germany; RRID:AB_309931)
and rabbit anti-A1R antibody (1:100; ab82477, Abcam,
Bristol, UK; RRID: AB_2049141)) was used to detect A1-
A2AHet together with PLA probes detecting mouse or
rabbit antibodies. Then, samples were processed for
ligation and amplification with a Detection Reagent Red
and were mounted using a DAPI-containing mounting
medium. Samples were analyzed in a Leica SP2 confocal
microscope (Leica Microsystems, Mannheim, Germany)
equipped with 405 nm and 561 nm laser lines. For each
field of view, a stack of two channels (one per staining) and
4–6 Z-stacks with a step size of 1 μm were acquired.
Images were opened and processed with Image J software
(National Institutes of Health, Bethesda, MD, USA).
cAMP determination assays
HEK-293 T cells expressing adenosine receptors were incu-
bated for 4 h in serum-free medium containing 50 μM zar-
deverine. Cells were plated in 384-well white microplates
(1500 cells/well), pre-treated with toxins or the correspond-
ing vehicle for the indicated time, stimulated with agonists
for 15 min before adding medium or 0.5 μM forskolin, and
incubated for an additional 15 min. cAMP production
was quantified by a TR-FRET (Time-Resolved Fluor-
escence Resonance Energy Transfer) methodology
using the LANCE Ultra cAMP kit (PerkinElmer) and
fluorescence at 665 nm was analyzed on a Pherastar
Flagship Microplate Reader (BMG Labtech, Orten-
berg, Germany).
Dynamic mass redistribution (DMR) assays
The heteromer-induced cell signaling signature was
determined using an EnSpire® Multimode Plate Reader
(PerkinElmer, Waltham, MA, USA) by a label-free
technology. Refractive waveguide grating optical biosen-
sors, integrated in 384-well microplates, allow extremely
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sensitive measurements of changes in local optical dens-
ity in a detecting zone up to 150 nm above the surface
of the sensor. Cellular mass movements induced upon
receptor activation were detected by illuminating the
underside of the biosensor with polychromatic light and
measured as changes in wavelength of the reflected
monochromatic light, which is a sensitive function of
the index of refraction. The magnitude of this wave-
length shift (in picometers) is directly proportional to
the amount of DMR. Briefly, 24 h before the assay, cells
were seeded at a density of 7500 cells per well in 384-
well sensor microplates with 40 μL growth medium and
cultured for 24 h (37 °C, 5% CO2) to obtain 70–80%
confluent monolayers. Previous to the assay, cells were
pre-treated with medium or toxins as indicated and in-
cubated for 2 h in 40 μL per well of assay-buffer (HBSS
with 20 mM HEPES, pH 7.15) in the reader at 24 °C.
Thereafter, the sensor plate was scanned and a baseline
optical signature was recorded prior to addition of 10 μL
of receptor agonist dissolved in assay buffer containing
0.1% DMSO. DMR responses were monitored for at
least 8000 s and data were analyzed using EnSpire
Workstation Software v. 4.10.
Computational modeling
The structural model of the A1-A2AHet bound to Gs
(closed αsAH domain) and Gi (closed αiAH domain) was
taken from our previous work [5]. This previous structural
model contains a A2AR-based homology model of A1R.
The structure of the adenosine A1R has recently been
revealed [31], showing a remarkably similar structure
(Additional file 1: Figure S6A). This structure of A1R con-
tains a TM4/5 dimer interface that is in close agreement
with our model (Additional file 1: Figure S6B). An inter-
mediate conformation (obtained using the g_morph tool of
the GROMACS package [32]) between the closed αAH do-
main (PDB id 1AZT) and the conformation observed in
the crystal structure of the β2-AR in complex with Gs (PDB
id 3SN6) was used to model the open αAH domain
(Additional file 1: Figure S6C). This conformation is sup-
ported by DEER spectroscopy, deuterium-exchange and
electron microscopy data [11–13]. The active state of
β-arrestin-2 was built using a multi-template alignment
combining the structure of the active β-arrestin-1 (PDB id
4JQI) [21] and the structure of rhodopsin in complex with
visual β-arrestin (PDB id 4ZWJ) [14]. Structural models of
the A1-A2AHet bound to β-arrestin-2 were modeled using
the crystal structure of rhodopsin bound to β-arrestin (PDB
id 4ZWJ) [14]. The structure of TM6 of A2AR fused to the
cell-penetrating TAT peptide was modeled from the struc-
ture of A2AR. Molecular models of the A1-A2AHet with the
TAT-fused TM6 peptide, disrupting the heteromer inter-
face between A1R and A2AR, in complex with Gs (open
αsAH domain) and Gi (open αiAH domain), was built from
the structure of A1-A2AHet. The conformation of the prox-
imal C-tail of A2AR (Ser305-Ala317) was modeled based on
squid rhodopsin [33]. The remaining part of the C-tail
(1Gly319–Ser412), cannot be unambiguously deter-
mined and it was modeled as suggested for the oxoeicosa-
noid receptor (OXER) [20], together with the structure
derived from the human V2 vasopressin receptor in com-
plex with β-arrestin-2 [21] (see Additional file 1: Figure S4
for details). Additional file 2: Table S1 shows the template
structures used in the protein models. Modeller 9.12 was
used to build these models [34]. The molecular models of
A1-A2AHet in complex with Gs and Gi or β-arrestin, in the
absence or presence of the TAT-fused TM6 peptide, were
embedded in a pre-equilibrated box containing a lipid bi-
layer (~800 POPC molecules) with explicit solvent
(~110,000 waters) and 0.15 M concentration of Na+ and
Cl– (~1800 ions). These initial complexes were energy-
minimized and subsequently subjected to a 21 ns MD
equilibration, with positional restraints on protein coordi-
nates. These restraints were released and 500 ns of MD
trajectory were produced at constant pressure and
temperature. Computer simulations were performed with
the GROMACS 4.6.3 simulation package [32], using the
AMBER99SB force field as implemented in GROMACS
and Berger parameters for POPC lipids. This procedure has
been previously validated [35].
Additional files
Additional file 1: Figures S1–S6. Figure S1. Control experiments on
the effect of interfering peptides on the A1-A2AHet structure and Gs and
Gi coupling to A1-A2AHet. Figure S2. Receptor signaling through A1R and
A2AR. Figure S3. Recruitment of β-arrestin-2 by the A1-A2AHet. Figure S4.
Modeling the orientation of the C-tail of A2AR. Figure S5. The influence
of the C-terminal domain of A2AR in the signaling properties of the
A1-A2AHet in the presence of pertussis toxin. Figure S6. Modeling
A1R homodimer and αsAH and αiAH in closed and open conformations.
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structures used to construct the computer models of A1-A2AHet in
complex with Gi and Gs. (PDF 23 kb)
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